Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. “2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. In each of these important areas, our leadership is expanding driven by game-changing science and technology.”
As the healthcare industry looks toward 2026, Johnson & Johnson (NYSE: JNJ) stands at a historic crossroads, reinforcing its reputation as the ultimate bellwether for the global healthcare sector. On the eve of its official fourth-quarter and full-year 2025 earnings release scheduled for January 21, 2026, the company has already signaled
In a bold move to transcend its identity as a legacy paper commodities giant, Kimberly-Clark (NYSE: KMB) has launched a massive $48.7 billion bid to acquire Kenvue (NYSE: KVUE), the consumer health powerhouse behind iconic brands like Tylenol and Neutrogena. The cash-and-stock deal, which represents one of the largest
As the global financial markets enter the first month of 2026, the dealmaking environment has shifted from a tentative recovery into a full-scale renaissance. Following a monumental 2025 that saw aggregate merger and acquisition (M&A) values surge to over $5 trillion—the second-highest level in history—market analysts and
As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results. This report serves as a critical barometer for the healthcare giant’s first full year as a
Johnson & Johnson's stock approaches its 52-week high due to positive Phase 3 CAPLYTA trial data, strong earnings momentum, and favorable market sentiment as it nears an upcoming earnings report.
Johnson & Johnson (NYSE: JNJ) to release Q4 earnings on Jan. 21, with analysts expecting $2.47/share. Recent news includes positive results for cancer drug and dividend yield of 2.38%.
Earnings season ramps up this week with some big names set to report. This week we have Netflix, Intel, Johnson & Johnson, Freeport McMoran and 3M Company all reporting in what shapes as a busy and pivotal week for stocks.
As of January 19, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different enterprise than the one most investors recognized just three years ago. Following the successful spin-off of its consumer health division, Kenvue, JNJ has fully transitioned into a high-growth, pure-play healthcare powerhouse focused exclusively on Innovative Medicine and Medical Technology (MedTech). [...]
Citigroup Inc. (NYSE: C) has emerged from its multi-year restructuring with a historic performance in its investment banking division, reporting record-breaking M&A advisory revenue for the 2025 fiscal year. Despite a volatile start to 2026 that saw the bank’s stock price dip following its fourth-quarter earnings release on
On January 15, 2026, Goldman Sachs (NYSE: GS) silenced critics of its strategic pivot by reporting a powerhouse fourth-quarter performance for 2025, headlined by a staggering $9.34 billion in annual investment banking fees. The firm’s earnings report showcased a definitive return to its roots as the world’s
In a definitive signal that the era of stagnant dealmaking has come to a close, Citigroup (NYSE:C) has reported record-breaking M&A advisory revenue for the fiscal year 2025. The results, unveiled on January 14, 2026, show a bank that has finally turned the corner on a grueling multi-year
As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a strategic pivot toward high-growth technology. Morgan Stanley (NYSE: MS) recently released a bullish outlook for the year, projecting a
As of January 15, 2026, Johnson & Johnson (NYSE: JNJ) has emerged as the undisputed pacesetter of the healthcare sector, with its stock price surging to an all-time high of $218.53. This milestone follows a year of aggressive restructuring and a landmark "TrumpRx" partnership that has provided the company with
Johnson & Johnson reports Phase 3 results showing Tecvayli reduced disease progression and deaths in multiple myeloma patients, beating standard treatments with manageable side effects.
In a stunning blow to the burgeoning field of allogeneic cell therapy, Atara Biotherapeutics (Nasdaq: ATRA) saw its market valuation evaporate this week following a second Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its lead candidate, tabelecleucel (Ebvallo). The regulatory setback, which the
